Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.EpiCept receives negative opinion for leukemia drug
In reaching this opinion, the European Committee for Medicinal Products for Human Use (CHMP) stated that further data are required to support the results from EpiCept’s Phase III
In reaching this opinion, the European Committee for Medicinal Products for Human Use (CHMP) stated that further data are required to support the results from EpiCept’s Phase III
Results from a Phase I study in onychomycosis, as well as preclinical data, indicated that the product can be safely applied to the skin at doses more than
Artiss was developed using Baxter’s proven fibrin sealant technology platform and is the newest agent in the company’s expanding BioSurgery portfolio. It is a biologically active sealant consisting
This includes a second generation recombinant Protective Antigen (rPA) anthrax vaccine, a recombinant dual antigen plague vaccine, and a third generation rPA anthrax vaccine program. As part of
The Treanda application as a chronic lymphocytic leukemia (CLL) treatment received priority review from the FDA and was approved within six months of the September 2007 submission. Cephalon
The open-label Phase Ib study will assess escalating doses of NPI-2358 in combination with docetaxel in patients with non-small cell lung cancer (NSCLC) who previously failed at least
The company’s US pivotal study is designed as an adaptive, randomized controlled trial at up to 30 sites in the US. Enrollment in the trial is expected to
Under the license agreement, Presidio becomes responsible for all further development and commercialization activities and costs relating to the program. XTL will receive an upfront payment of $4
The recall decision resulted from the ongoing monitoring of marketed product, which revealed a deviation from the approved product specification. As a result, there will be an out-of-stock
This patent family, owned exclusively by Alnylam, covers fundamental aspects of the structure and uses of RNAi products including their use to mediate RNAi in mammalian cells and